| Literature DB >> 36088290 |
Niloufar Bineshfar1, Ali Rezaei1, Alireza Mirahmadi1, Mehrdad Haghighi2, Ali Amini Harandi3, Maziar Shojaei4, Mahtab Ramezani5, Anahita Zoghi5, Kourosh Gharagozli5, Shervin Shokouhi2,6, Farid Javandoust Gharehbagh2, Legha Lotfollahi7, Ilad Alavi Darazam8,9.
Abstract
BACKGROUND: Meningitis is known as a meningeal inflammation accompanied by pleocytosis in the cerebrospinal fluid (CSF), and can be classified into acute, subacute, and chronic meningitis based on symptoms duration of ≤ 5 days, ≥ 5 days and ≥ 4 weeks, respectively. Subacute and chronic meningitis are caused mainly by indolent infectious agents and noninfectious causes such as autoimmune, and neoplastic. In this study, we investigated the characteristics, diagnosis, and treatment of subacute and chronic meningitis.Entities:
Keywords: CNS infection; Chronic meningitis; Epidemiology; Subacute meningitis; Tuberculosis
Mesh:
Year: 2022 PMID: 36088290 PMCID: PMC9463760 DOI: 10.1186/s12883-022-02873-1
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.903
Detailed patients' characteristics compared between etiology groups
| Characteristics | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total | Autoimmune | Viral | Bacterial, excluding TB | TB | Neoplastic | No definite diagnosis | ||
| Age, mean, years | 37.3 | 39 | 18 | 35.1 | 29.7 | 57.4 | 37.2 | |
| Gender | ||||||||
| male | 53/79 (67.1) | 1(100) | 1 (100) | 7 (70.0) | 8 (53.3) | 2 (25.0) | 34 (77.3) | |
| female | 26/79 (32.9) | 0 | 0 | 3 (30.0) | 7 (46.7) | 6 (75.0) | 10 (22.7) | |
| Symptoms | ||||||||
| Duration, mean, days | 32.7 | 30 | 6 | 59.3 | 33.5 | 31.1 | 25.9 | 0.70 |
| Headache | 69/79 (87.3) | 1(100) | 1 (100) | 10 (100) | 14 (93.3) | 3 (37.5) | 40 (90.9) | |
| Fever | 44/78 (56.4) | 0 | 1 (100) | 5 (50.0) | 15 (100) | 1 (12.5) | 22 (51.2) | |
| Nausea/vomiting | 59/79 (74.7) | 0 | 1 (100) | 7 (70.0) | 12 (80.0) | 5 (62.5) | 34 (77.3) | 0.75 |
| Neurological symptomsa | 31/79 (39.2) | 0 | 0 | 3 (30.0) | 9 (60.0) | 6 (75.0) | 13 (29.5) | |
| Visual impairment | ||||||||
| Blurred vision | 23/79 (29.1) | 1(100) | 1 (100) | 4 (40.0) | 3 (20.0) | 3 (37.5) | 11 (25.0) | 0.41 |
| Diplopia | 18/79 (22.8) | 0 | 0 | 4 (40.0) | 4 (26.7) | 3 (37.5) | 7 (15.9) | |
| Photophobia | 3/79 (3.8) | 0 | 0 | 0 | 1 (6.7) | 0 | 2 (4.5) | |
| Seizure | 11/72 (15.3) | 0 | 0 | 1 (11.1) | 3 (20.0) | 1 (12.5) | 6 (15.8) | 0.96 |
| Night sweats | 5/79 (6.4) | 0 | 0 | 0 | 2 (13.3) | 0 | 3 (7.0) | 0.72 |
| Weight loss | 6/79 (7.6) | 0 | 0 | 1 (10.0) | 2 (13.3) | 1 (12.5) | 2 (4.5) | 0.38 |
| Dyspnea | 2/79 (2.5) | 0 | 0 | 0 | 0 | 0 | 2 (4.5) | 1.00 |
| Cough | 5/79 (6.3) | 0 | 0 | 0 | 1 (6.7) | 1 (12.5) | 3 (6.8) | 0.80 |
| Tinnitus | 1/79 (1.3) | 0 | 0 | 0 | 0 | 0 | 1 (2.3) | 1.00 |
| Medical history | ||||||||
| Immunosuppressionb | 2/79 (2.5) | 0 | 0 | 1 | 1 | 0 | 0 | - |
| Malignancy | 8/79 (10.1) | 0 | 0 | 0 | 0 | 6 | 2 | - |
| Signs | ||||||||
| Altered mental status | 21/78 (26.9) | 0 | 0 | 1 (11.1) | 8 (53.3) | 3 (37.5) | 9 (20.5) | 0.57 |
| Nuchal rigidity | 24/53 (45.3) | 0 | 0 | 6 (75.0) | 8 (72.7) | 0 | 10 (34.5) | |
| Papillary edema | 9/24 (37.5) | 1(100) | 0 | 2 (20.0) | 0 | 1 (12.5) | 5 (11.4) | |
| Laboratory analysis | ||||||||
| WBC count, mean, × 109/L | 9.8 | 11.2 | 8.5 | 13.9 | 10.4 | 6.2 | 9.1 | |
| CSF analysis | ||||||||
| WBC count, mean, cells/mm3 | 1248.3 | 40 | 740 | 8199.4 | 201.6 | 334.5 | 380.3 | 0.50 |
| Pleocytosis | ||||||||
| Neutrophilic | 24/62 (38.7) | 1(100) | 0 | 6 (100) | 2 (15.4) | 1 (25.0) | 14 (37.8) | |
| Monocytic | 34/62 (54.8) | 0 | 1 (100) | 0 | 10 (76.9) | 3 (75.0) | 20 (54.1) | |
| Lymphocytic | 4/62 (6.5) | 0 | 0 | 0 | 1 (7.7) | 0 | 3 (8.1) | |
| Elevated Protein | 49/67 (73.1) | 0 | 1 (100) | 6 (75.0) | 11 (91.7) | 4 (100) | 27 (65.9) | 0.24 |
| Decreased glucose | 47/54 (87.0) | 1(100) | 0 | 5 (83.3) | 11 (100) | 3 (75) | 27 (87.1) | 0.43 |
| Radiology | ||||||||
| Normal Brain CT scan | 24/35 (68.6) | - | - | 3 (75) | 6 (60) | 1 (50) | 14 (73.7) | 0.75 |
| Normal Brain MRI | 15/25 (60.0) | 0 | - | 2 (100) | 2 (33.3) | 1 (33.3) | 10 (76.9) | |
| Management | ||||||||
| Steroid therapy | 30/79 (38.0) | 1(100) | 1 (100) | 2 (20) | 6 (40) | 7 (87.5) | 14 (31.8) | 0.06 |
| Anti-TB therapy | 25/77 (32.5) | 0 | 0 | 0 | 15 (100) | 0 | 11 (25.6) | |
| Empirical acyclovir therapy | 23/64 (35.9) | - | 1 (100) | 3 (33.3) | 7 (46.7) | 2 (40) | 10 (29.4) | 0.53 |
| Empirical antibiotic therapy | 55/60 (91.7) | - | 0 | 8 (100) | 10 (90.9) | 3 (60) | 34 (97.1) | |
| Death | ||||||||
TB Tuberculosis, WBC White blood cells, CSF Cerebrospinal fluid, CT Computed tomography, MRI Magnetic resonance imaging.
a Focal neurologic deficits and altered level and content of consciousness.
b History of HIV (human immunodeficiency virus) or immunosuppressant medications.
‡ The comparisons have been made among etiology groups (bacterial, TB, neoplastic, and no definite diagnosis.)
Detailed patients' characteristics compared between subacute and chronic meningitis
| Subacute ( | Chronic ( | ||
|---|---|---|---|
| 34.2 | 39.4 | 0.13 | |
| | 23/32 (71.9) | 30/47 (63.8) | 0.48 |
| | 9/32 (28.1) | 17/47 (36.2) | |
| | 29/32 (90.6) | 40/47 (85.1) | 0.73 |
| | 24/32 (75.0) | 20/46 (43.5) | |
| | 29/32 (90.6) | 30/47 (63.8) | |
| | 7/32 (21.9) | 24/47 (51.1) | |
| | |||
| | 10/32 (31.3) | 13 (27.7) | 0.29 |
| | 4/32 (12.5) | 14/47 (29.8) | |
| | 1/32 (3.1) | 2/47 (4.3) | |
| | 1/32 (3.1) | 5/47 (10.6) | 0.39 |
| | 1/31 (3.2) | 4/47 (8.5) | 0.64 |
| | 5/30 (16.7) | 6/42 (14.3) | 1.00 |
| | 1/32 (3.1) | 1/47 (2.1) | 1.00 |
| | 1/32 (3.1) | 4/47 (8.5) | 0.64 |
| | 1/32 (3.1) | 0/47 | 0.40 |
| | 10/32 (31.3) | 11/46 (23.9) | |
| | 13/24 (54.2) | 11/29 (37.9) | 0.27 |
| | 2/10 (20.0) | 7/14 (50.0) | 0.21 |
| | 10.8 | 9.0 | 0.18 |
| | |||
| | 2244.3 | 482.1 | |
| | |||
| | 7/29 (24.1) | 17/33 (51.5) | |
| | 22/29 (75.9) | 12/33 (36.4) | |
| | 0/29 | 4/33 (12.1) | |
| | 23/29 (79.3) | 26/38 (68.4) | 0.40 |
| | 25/27 (92.6) | 22/27 (81.5) | 0.42 |
| | 13/17 (76.5) | 11/18 (61.1) | 0.39 |
| | 6/8 (75.0) | 9/17 (52.9) | 0.67 |
| | 14/32 (43.8) | 17/35 (48.6) | 0.80 |
| | 13/32 (40.6) | 13/45 (28.9) | 0.33 |
| | 11/31 (35.5) | 12/33 (36.4) | 1.00 |
| | 28/30 (93.3) | 27/30 (90.0) | 1.00 |
WBC White blood cells, CSF Cerebrospinal fluid, CT Computed tomography, MRI Magnetic resonance imaging, TB Tuberculosis
a Focal neurologic deficits and altered level and content of consciousness
Detailed etiologies of neoplastic and bacterial causes
| Etiologies | Patients, No |
|---|---|
| Neoplastic ( | |
| B-cell lymphoma | 2 |
| Breast cancer | 2 |
| Lung cancer | 1 |
| CLL | 1 |
| Unknown origin | 2 |
| Bacterial excluding tuberculosis ( | |
| | 3 |
| | 2 |
| | 2 |
| | 2 |
| | 1 |
CLL Chronic lymphocytic leukemia
Diagnostic tests performed on patients with no definite diagnosis (n = 44)
| Tests | Patients, No. (%) |
|---|---|
| Microbiology analysis | |
| Gram stain | 15 (34.11) |
| Indian ink stain | 1 (2.3) |
| Cultures | |
| Blood culture | 42 (95.5) |
| CSF bacterial culture | 42 (95.5) |
| CSF fungal culture | 13 (29.5) |
| Serology tests | |
| VDRL or RPR | 17 (38.6) |
| Wright or 2ME | 19 (43.2) |
| Cryptococcal antigen | 4 (9.0) |
| CSF cytology | 4 (9.0) |
| CSF PCR tests | |
| TB | 6 (13.6) |
| HSV | 6 (13.6) |
| BK virus | 2 (4.5) |
| CMV | 3 (6.8) |
| Brain biopsy | 2 (4.5) |
CSF Cerebrospinal fluid, VDRL Venereal disease research laboratory test, RPR Rapid plasma reagain, 2ME 2-Mercaptoethanol, PCR Polymerase chain reaction, TB Tuberculosis, HSV Herpes simplex virus, CMV Cytomegalovirus